NOS2 and breast cancer: Along similar lines, inhibition of nitric oxide (NO) production by MDSCs with a nitric oxide synthase 2 (NOS2) inhibitor reportedly restores NK-cell mediated ADCC in preclinical models of breast cancer, resulting in superior tumor control in vivo [117].